Wolfgang Miesbach/LinkedIn
Dec 7, 2025, 16:21
Wolfgang Miesbach: Beyond Immunosuppression – Two new ways to treat ITP
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
“Beyond Immunosuppression: Two new ways to treat ITP. David Kuter gave a great presentation at ASH 2025:
- Increase Platelet Production
The latest TPO receptor agonist, hetrombopag, now in Phase 3 trials, offers a direct pathway to boost platelet synthesis—moving away from suppression toward restoration. - Decrease Platelet Destruction
A diverse arsenal of targeted therapies can redefineour strategy:
– Anti-CD38 antibodies (daratumumab, mezagitamab)
– BAFF/BAFF-R inhibitors
– FcRn inhibitors (efgartigimod)
– BTK inhibitors (rilzabrutinib, orelabrutinib)
– Complement inhibitors + immunomodulatory approaches
– T-cell engagers and CAR-T therapies
ITP is now recognized as a disorder of both reduced production AND increased destruction—this understanding drives treatment selection toward complete remission, not just disease suppression.”
Find the full coverage of ASH25 in Hemostasis Today.
-
May 22, 2026, 17:30Veronica Sanchez: Do You Live with Pain after a Stroke?
-
May 22, 2026, 17:25Maxime Dely: A Simple but Powerful Indicator of Platelet Quality
-
May 22, 2026, 17:24Jim Hoffman: A New Approach to Balancing Host Defense and Tissue Protection
-
May 22, 2026, 17:22Lucia Rugeri: Advancing Multidisciplinary Care for Heavy Menstrual Bleeding in Women with Bleeding Disorders
-
May 22, 2026, 17:20Nour Al-Mozain: Optimizing PBSC Collection Through Real-Time CD34+ Monitoring
-
May 22, 2026, 16:30Buse Bor: New Publication on Therapeutic Interventions for Women with Obstetric APS
-
May 22, 2026, 16:29Danny Hsu: The Reversal Dilemma – Rethinking our approach to DOAC-associated ICH
-
May 22, 2026, 16:28Bartosz Hudzik: High Bleeding Risk Does Not Always Mean Bleeding-Risk Predominance
-
May 22, 2026, 16:26Sandeep De: Omicron COVID Infections Linked to Coronary Thrombosis without Detectable Plaque